Ixico selected for Huntington's disease detection study

Artificial intelligence (AI) neuroimaging company Ixico announced on Thursday that it has been selected by a new client to support a global prospective observational study, assessing participants for the early detection of Huntington's disease (HD).

The AIM-traded firm described HD as a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain, affecting movement, mood and thinking abilities.

It described the unnamed client as a biotechnology company specialised in gene therapy for neurodegenerative and other genetic diseases.

Ixico would provide a range of its imaging contract research and advanced analytics services across about two-and-a-half years.

“With no current cure for Huntington's, nor interventions that slow disease progression, HD is a devastating rare neurological condition with significant unmet medical needs,” said chief executive officer Giulio Cerroni.

“We are delighted to further extend our client base and support identifying new insights into this challenging rare neurodegenerative disease.

“We are committed to ensuring that our validated machine learning AI data analytics, combined with the quality assurance of our TrialTracker platform, enable clients to unlock new insights into disease progression and drug development.”

At 1133 BST, shares in Ixico were up 1.89% at 36.68p.